Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Dec;17(4):303-9.
doi: 10.1023/a:1021905801401.

Nitric oxide in patients with cirrhosis and bacterial infections

Affiliations
Review

Nitric oxide in patients with cirrhosis and bacterial infections

José Such et al. Metab Brain Dis. 2002 Dec.

Abstract

Nitric oxide (NO) is a powerful vasodilator agent that has been found to be elevated in patients with cirrhosis, and that plays a key role in the pathogenesis of the hemodynamic abnormalities found in these patients. The reasons for this increased NO synthesis are not entirely known, but at least two main mechanisms are involved: shear stress and bacterial-induced NO synthesis. This review focuses on bacterial-induced NO synthesis. Induction of NO synthesis by different cellular populations occurs when proinflammatory cytokines act synergistically, and also by endotoxin. Spontaneous bacterial peritonitis (SBP) is the most dangerous infectious complication arising in patients with cirrhosis and ascites, and it is associated with high serum and ascitic fluid levels of proinflammatory cytokines. A subset of patients in this situation show high levels of serum and ascitic fluid NO levels when SBP is diagnosed, and these patients seem to be predisposed to the development of renal impairment. The increased NO synthesis and associated aggravated vasodilatation may be the reason why patients with SBP show high levels of plasma renin activity, in an attempt to counterbalance this new situation, and that the administration of albumin during the SBP episode significantly reduces the episode-related mortality.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Hepatol. 1997 Jan;26(1):75-80 - PubMed
    1. Cell. 1995 May 19;81(4):641-50 - PubMed
    1. Am J Physiol. 1996 Mar;270(3 Pt 2):F494-9 - PubMed
    1. J Hepatol. 1993 Jul;18(3):353-8 - PubMed
    1. Hepatology. 2002 Jul;36(1):135-41 - PubMed

MeSH terms

LinkOut - more resources